Patents by Inventor Paul G. Ambrose
Paul G. Ambrose has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220215922Abstract: A computer system, computer program product and method for determining a probability of attaining a PK-PD target associated with efficacy for a patient that includes a processor obtaining information identifying an infection and based on the information, generating and displaying, by the one or more processors, a list comprising one or more pathogens consistent with the information, the processor then obtaining a first indication designating at least one pathogen from the list comprising one or more pathogens and based on at the obtaining of the least one pathogen, generating a list comprising one or more drug therapies utilized to treat the at least one pathogen.Type: ApplicationFiled: January 14, 2022Publication date: July 7, 2022Inventors: Paul G. Ambrose, Sujata Bhavnani, Christopher M. Rubino
-
Patent number: 11227680Abstract: A computer system, computer program product and method for determining a probability of attaining a PK-PD target associated with efficacy for a patient that includes a processor obtaining information identifying an infection and based on the information, generating and displaying, by the one or more processors, a list comprising one or more pathogens consistent with the information, the processor then obtaining a first indication designating at least one pathogen from the list comprising one or more pathogens and based on at the obtaining of the least one pathogen, generating a list comprising one or more drug therapies utilized to treat the at least one pathogen.Type: GrantFiled: January 13, 2020Date of Patent: January 18, 2022Assignee: PRXCISION LLCInventors: Paul G. Ambrose, Sujata Bhavnani, Christopher M. Rubino
-
Patent number: 10751303Abstract: Methods of shortening the duration of anti-infective therapy and increasing the effectiveness of anti-infective drugs in subjects with infection are present. The methods are based on altering the replication rate of a pathogen, which makes the pathogen more susceptible to the actions of the anti-infective drug.Type: GrantFiled: September 27, 2017Date of Patent: August 25, 2020Assignee: INSTITUTE FOR CLINICAL PHARMACODYNAMICS, INC.Inventor: Paul G. Ambrose
-
Publication number: 20200152307Abstract: A computer system, computer program product and method for determining a probability of attaining a PK-PD target associated with efficacy for a patient that includes a processor obtaining information identifying an infection and based on the information, generating and displaying, by the one or more processors, a list comprising one or more pathogens consistent with the information, the processor then obtaining a first indication designating at least one pathogen from the list comprising one or more pathogens and based on at the obtaining of the least one pathogen, generating a list comprising one or more drug therapies utilized to treat the at least one pathogen.Type: ApplicationFiled: January 13, 2020Publication date: May 14, 2020Inventors: Paul G. Ambrose, Sujata Bhavnani, Christopher M. Rubino
-
Patent number: 10534895Abstract: A computer system, computer program product and method for determining a probability of attaining a PK-PD target associated with efficacy for a patient that includes a processor obtaining information identifying an infection and based on the information, generating and displaying, by the processor, a list comprising one or more pathogens consistent with the information, the processor then obtaining a first indication designating at least one pathogen from the list comprising one or more pathogens and based on at the obtaining of the least one pathogen, generating a list comprising one or more drug therapies utilized to treat the at least one pathogen.Type: GrantFiled: January 20, 2015Date of Patent: January 14, 2020Assignee: ICPD Technologies, LLCInventors: Paul G. Ambrose, Sujata Bhavnani, Christopher M. Rubino
-
Publication number: 20190134070Abstract: An improved method for identifying the size, shape and duration of drug exposure necessary to improve drug treatment in a subject with a bacterial infection. In addition, an improved method for identification of new dosing strategies which optimize the probability of positive treatment outcomes in subjects using resistance inhibitory concentration (RIC), wherein the subject has a bacterial infection caused by a bacterium with a propensity for heteroresistance. Further, an improved method for decreasing the potential for on-therapy drug resistance by determining a patient's RIC prior to administration of fosfomycin treatment, wherein RIC is utilized to differentiate the parameter which is best related to the driver or index of fosfomycin efficacy for the resistant subpopulation present and the required inhibitory concentration of those mutants.Type: ApplicationFiled: October 2, 2018Publication date: May 9, 2019Inventors: Paul G. Ambrose, Evelyn Ellis-Grosse
-
Patent number: 10086006Abstract: An improved method for identifying the size, shape and duration of drug exposure necessary to improve drug treatment in a subject with a bacterial infection. In addition, an improved method for identification of new dosing strategies which optimize the probability of positive treatment outcomes in subjects using resistance inhibitory concentration (RIC), wherein the subject has a bacterial infection caused by a bacterium with a propensity for heteroresistance. Further, an improved method for decreasing the potential for on-therapy drug resistance by determining a patient's RIC prior to administration of fosfomycin treatment, wherein RIC is utilized to differentiate the parameter which is best related to the driver or index of fosfomycin efficacy for the resistant subpopulation present and the required inhibitory concentration of those mutants.Type: GrantFiled: April 22, 2016Date of Patent: October 2, 2018Assignee: Zavante Therapeutics, Inc.Inventors: Paul G. Ambrose, Evelyn Ellis-Grosse
-
Publication number: 20180015055Abstract: Methods of shortening the duration of anti-infective therapy and increasing the effectiveness of anti-infective drugs in subjects with infection are present. The methods are based on altering the replication rate of a pathogen, which makes the pathogen more susceptible to the actions of the anti-infective drug.Type: ApplicationFiled: September 27, 2017Publication date: January 18, 2018Applicant: INSTITUTE FOR CLINICAL PHARMACODYNAMICS, INC.Inventor: Paul G. AMBROSE
-
Patent number: 9795572Abstract: Methods of shortening the duration of anti-infective therapy and increasing the effectiveness of anti-infective drugs in subjects with infection are present. The methods are based on altering the replication rate of a pathogen, which makes the pathogen more susceptible to the actions of the anti-infective drug.Type: GrantFiled: January 26, 2016Date of Patent: October 24, 2017Assignee: INSTITUTE FOR CLINICAL PHARMACODYNAMICS, INC.Inventor: Paul G. Ambrose
-
Publication number: 20170065539Abstract: Methods of shortening the duration of anti-infective therapy and increasing the effectiveness of anti-infective drugs in subjects with infection are present. The methods are based on altering the replication rate of a pathogen, which makes the pathogen more susceptible to the actions of the anti-infective drug.Type: ApplicationFiled: January 26, 2016Publication date: March 9, 2017Applicant: INSTITUTE FOR CLINICAL PHARMACODYNAMICS, INC.Inventor: Paul G. Ambrose
-
Publication number: 20170020902Abstract: An improved method for identifying the size, shape and duration of drug exposure necessary to improve drug treatment in a subject with a bacterial infection. In addition, an improved method for identification of new dosing strategies which optimize the probability of positive treatment outcomes in subjects using resistance inhibitory concentration (RIC), wherein the subject has a bacterial infection caused by a bacterium with a propensity for heteroresistance. Further, an improved method for decreasing the potential for on-therapy drug resistance by determining a patient's RIC prior to administration of fosfomycin treatment, wherein RIC is utilized to differentiate the parameter which is best related to the driver or index of fosfomycin efficacy for the resistant subpopulation present and the required inhibitory concentration of those mutants.Type: ApplicationFiled: April 22, 2016Publication date: January 26, 2017Inventors: Paul G. Ambrose, Evelyn Ellis-Grosse
-
Publication number: 20160210436Abstract: A computer system, computer program product and method for determining a probability of attaining a PK-PD target associated with efficacy for a patient that includes a processor obtaining information identifying an infection and based on the information, generating and displaying, by the processor, a list comprising one or more pathogens consistent with the information, the processor then obtaining a first indication designating at least one pathogen from the list comprising one or more pathogens and based on at the obtaining of the least one pathogen, generating a list comprising one or more drug therapies utilized to treat the at least one pathogen.Type: ApplicationFiled: January 20, 2015Publication date: July 21, 2016Inventors: Paul G. Ambrose, Sujata Bhavnani, Christopher M. Rubino
-
Patent number: 9345717Abstract: An improved method for identifying the size, shape and duration of drug exposure necessary to improve drug treatment in a subject with a bacterial infection. In addition, an improved method for identification of new dosing strategies which optimize the probability of positive treatment outcomes in subjects using resistance inhibitory concentration (RIC), wherein the subject has a bacterial infection caused by a bacterium with a propensity for heteroresistance. Further, an improved method for decreasing the potential for on-therapy drug resistance by determining a patient's RIC prior to administration of fosfomycin treatment, wherein RIC is utilized to differentiate the parameter which is best related to the driver or index of fosfomycin efficacy for the resistant subpopulation present and the required inhibitory concentration of those mutants.Type: GrantFiled: September 25, 2014Date of Patent: May 24, 2016Assignee: Zavante Therapeutics, Inc.Inventors: Paul G. Ambrose, Evelyn Ellis-Grosse
-
Publication number: 20150148315Abstract: An improved method for identifying the size, shape and duration of drug exposure necessary to improve drug treatment in a subject with a bacterial infection. In addition, an improved method for identification of new dosing strategies which optimize the probability of positive treatment outcomes in subjects using resistance inhibitory concentration (RIC), wherein the subject has a bacterial infection caused by a bacterium with a propensity for heteroresistance. Further, an improved method for decreasing the potential for on-therapy drug resistance by determining a patient's RIC prior to administration of fosfomycin treatment, wherein RIC is utilized to differentiate the parameter which is best related to the driver or index of fosfomycin efficacy for the resistant subpopulation present and the required inhibitory concentration of those mutants.Type: ApplicationFiled: September 25, 2014Publication date: May 28, 2015Inventors: Paul G. Ambrose, Evelyn Ellis-Grosse